Preclinical Imaging Market to Reach USD 9.0 Billion by 2034 at 8.0% CAGR - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - Chronic diseases now account for 71% of all deaths worldwide, according to the World Health Organization, a burden that is pushing pharmaceutical and biotechnology researchers to lean more heavily on preclinical imaging to understand disease mechanisms and evaluate new therapies before they reach human trials. That disease burden sits behind a new market study from Strategic Revenue Insights, which values the global Preclinical Imaging market at USD 4.5 billion in 2025 and projects it will reach USD 9.0 billion by 2034, a CAGR of 8.00% over the forecast period. "Researchers are under pressure to move faster against a growing chronic disease burden, and imaging is one of the few tools that lets them see whether a candidate therapy is working before it ever reaches a patient," said lead analyst Lukas Schmidt. The findings draw on primary interviews with pharmaceutical and biotechnology researchers, imaging system manufacturers, and contract research organizations, combined with secondary research across Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Key Takeaways

• The Preclinical Imaging market was valued at USD 4.5 billion in 2025 and is forecast to reach USD 9.0 billion by 2034, growing at a CAGR of 8.00%.
• Imaging Systems hold the largest share by product, while Multimodal Systems are the fastest-growing segment as researchers seek more comprehensive, integrated imaging solutions.
• The integration of AI and machine learning into imaging systems is improving accuracy, reducing human error, and accelerating high-throughput research workflows.
• North America leads the market due to advanced healthcare infrastructure, while Asia Pacific is expected to post the highest growth rate as regional research investment expands.
• Bruker, Siemens Healthineers, and Fujifilm VisualSonics lead the competitive landscape, each backed by strong global distribution and sustained R&D investment.

Full report access: https://www.strategicrevenueinsights.com/industry/preclinical-imaging-market

Chronic Disease Burden Is Pushing Imaging Deeper Into the Drug Development Pipeline

The World Health Organization's finding that chronic diseases cause 71% of deaths globally is driving sustained investment in tools that can speed up therapeutic development, and preclinical imaging sits squarely in that pipeline by helping researchers visualize and understand complex biological processes before a candidate drug advances further. Government initiatives and funding aimed at advancing healthcare research are reinforcing that investment, supporting adoption of imaging technologies across the drug discovery process.

Technology is reshaping what these systems can do. The industry's traditional focus on standalone imaging systems is giving way to integrated, multimodal solutions that combine multiple imaging techniques to give researchers a more holistic view of biological processes, a shift particularly pronounced in oncology and neurology research where understanding intricate disease mechanisms is essential. AI and machine learning are compounding this shift by enabling real-time data processing and analysis, which is especially valuable in high-throughput screening environments where speed and accuracy both matter.

Cost and regulatory pressure are shaping how companies compete. As healthcare budgets tighten, manufacturers are being pushed to develop imaging systems that deliver high performance at lower cost, while stricter government regulation of medical research and imaging technologies is driving increased investment in regulatory affairs and quality assurance to ensure compliance and maintain product safety and efficacy standards.

Market Segmentation

By modality, Micro-MRI and Micro-PET & Micro-SPECT are widely used for their high-resolution imaging capabilities in detailed anatomical and functional studies, while demand for Multimodal Systems is rising as researchers seek comprehensive solutions that combine multiple modalities; Micro-CT and Optical Imaging are also gaining popularity for their non-invasive nature in oncology and cardiovascular research.

By product, Imaging Systems hold the largest share given their widespread use across research applications, while Software & Analysis Tools are gaining traction as they add advanced data analysis capabilities that improve study efficiency and accuracy; Reagents & Contrast Agents remain an important segment as new formulations enhance imaging capabilities across modalities.

By application, Oncology Research is the largest application segment, driven by the increasing prevalence of cancer and the need for more effective treatments, while Neurology and Cardiovascular Research are also significant and growing segments as researchers work to understand complex disease mechanisms; Drug Discovery & Pharmacokinetics is a further important application area for evaluating the efficacy and safety of new drugs.

By end use, Pharmaceutical Companies are the largest end-use segment, relying heavily on preclinical imaging for drug discovery and development, while Biotechnology Companies and Contract Research Organizations are also significant users requiring advanced imaging to support their research activities; Academic & Research Institutes round out the end-use base, relying on these technologies for basic research into biological processes.

Regional Outlook

North America is the largest regional market, underpinned by advanced healthcare infrastructure. Asia Pacific is expected to post the highest growth rate, supported by increasing investment in healthcare research and development across the region. Latin America is also named as a region benefiting from rising healthcare research investment, and Europe and Middle East & Africa round out the report's regional coverage.

Competitive Landscape

Bruker, Siemens Healthineers, and Fujifilm VisualSonics lead the Preclinical Imaging market. Bruker is known for its comprehensive range of imaging systems and solutions, with a focus on developing technologies that enhance imaging accuracy and efficiency. Siemens Healthineers offers a wide range of imaging solutions for various research applications, supported by a strong global presence and extensive distribution network. Fujifilm VisualSonics is renowned for its high-frequency ultrasound imaging systems widely used in preclinical research, built on a track record of innovation and product development. Other notable players named in the report include Mediso, MR Solutions, and Trifoil Imaging, all investing in R&D to develop advanced imaging solutions for the research community.

Market Restraints

The high cost of advanced imaging systems is a key restraint, creating a barrier to adoption for smaller research institutions and companies, particularly in regions with limited healthcare budgets. Increasing regulatory scrutiny on imaging technologies is a second restraint, as companies must navigate complex regulatory landscapes that can increase costs and delay product development.

Related Reports

https://www.strategicrevenueinsights.com/industry/polypropylene-homopolymer-market

https://www.strategicrevenueinsights.com/industry/pvc-vertical-railing-systems-market

https://www.strategicrevenueinsights.com/industry/recyclable-thermoforms-market

https://www.strategicrevenueinsights.com/industry/recyclable-thermoset-resins-market

https://www.strategicrevenueinsights.com/industry/recycling-water-filtration-market

Frequently Asked Questions

What is the Preclinical Imaging market size in 2025?

The Preclinical Imaging market was valued at USD 4.5 billion in 2025 and is projected to reach USD 9.0 billion by 2034, growing at a CAGR of 8.00%.

What is driving growth in the Preclinical Imaging market?

Growth is driven by increasing demand for advanced imaging technologies in drug discovery and development, along with technological advancements in imaging systems.

Which region leads the Preclinical Imaging market?

North America is the largest regional market due to advanced healthcare infrastructure, while Asia Pacific is expected to witness the highest growth rate.

Who are the leading companies in the Preclinical Imaging market?

Bruker, Siemens Healthineers, and Fujifilm VisualSonics are the leading companies, with Mediso, MR Solutions, and Trifoil Imaging also active in the market.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases